News | November 28, 2025
GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
GV20 received an upfront payment and is eligible for additional milestone payments
GV20 received an upfront payment and is eligible for additional milestone payments
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
Subscribe To Our Newsletter & Stay Updated
